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Non-specific beneficial effect of measles immunisation: analysis of 
mortality studies from developing countries 
Peter Aaby, Badara Samb, Francois Simondon, Awa Marie Coll Seck, Kim Knudsen, Hilton Whittle 
Absbact 
Objective-To examine whether the reduction in 
mortality after standard titre measles immunisation 
in developing countries can be explained simply by 
the prevention of acute measles and its long term 
consequences. 
Design-An analysis of all studies comparing 
mortality of unimmunised children and children 
immunised with standard titre measles vaccine in  
developing countries. 
Studies-10 cohort and two case-control studies 
from Bangladesh, Benin, Burundi, Guinea-Bissau, 
Haiti, Senegal, and Zaire. 
Main outcome measures-Protective efficacy of 
standard titre measles immunisation against all 
cause mortality. Extent to which difference in 
mortality between immunised and unimmunised 
children could be explained by prevention of measles 
disease. 
Results--Protective efficacy against death after 
measles immunisation ranged from 30% to 86%. 
Efficacy was highest in the studies with short follow 
up and when children were immunised in infancy 
(range 44-1OOo/o). Vaccine efficacy against death 
was much greater than the proportion of deaths 
attributed to acute measles disease. In four studies 
from Guinea-Bissau, Senegal, and Burundi vaccine 
efficacy against death remained almost unchanged 
when cases of measles were excluded from the 
analysis. Diphtheria-tetanus-pertussis and polio 
vaccinations were not associated with reduction in 
mortality. 
Conclusion-These observations suggest that 
standard titre measles vaccine may confer a bene- 
ficial effect which is unrelated to the specific protec- 
tion a g e s t  measles disease. 
Introduction 
Evaluation; of immunisation programmes are 
usually based on the assumption that vaccines have an 
impact only against specific diseases. This assumption 
may not be correct for measles vaccine. Recent studies 
indicate $at vaccines may have important non-specific 
effects as girls receiving high titre measles vaccines 
werë found to have reduced long term survival com- 
pared with recipients of standard titre vaccines.IJ On 
the other hand, studies of standard titre measles 
vaccine have reported a greater than expected reduc- 
tion in mortality in areas with high mortality..'" As 
these observations suggest that measles immunisation 
may have a non-specific, beneficial effect' we reviewed 
mortality studies of unvaccinated and vaccinated 
children and examined whether the reduction in 
mortality after measles immunisation is due only to the 
specific prevention of acute measles disease and its 
long term consequences. If mkasles vaccines have 
non-specific, beneficial effects the age at immunisation 
and the number of doses of vaccines should be 
reconsidered: -Furthermore, new measles vaccines 
would have to be evaluated for their impact on survival 
before being introduced, and immunisation would 
have to continue after possible eradication of measles 
unless the same beneficial effects could be produced 
through other means. 
Studies and methods 
STUDIES OF STANDARD TITRE MEASLES VACCINE 
We reviewed Index Medicus from 1970 onwards for 
studies dealing with mortality after standard titre 
measles vaccination. Table I shows the available 
studies with information on mortality among 
immunised and unimmunised children. We found 10 
follow up studies and two casekontrol studies which 
had examined the impact of Schwarz standard titre 
measles vaccine. 
STUDIES OF DIPHTHERIA-TETANUS-PERTUSSIS A N D  P O U 0  
IMMUNISATION 
Reduced mortality among recipients of standard 
titre measles vaccine compared with unimmunised 
children could be due to a selection bias between those 
children who attended and those who did not attend 
clinics for measles vaccination. We therefore examined 
whether diphtheria-tetanus-pertussis and polio vacd- 
nation was associated with a similar reduction in the 
areas where measles vaccine had also been examined. 
Attendance for diphtheria-tetanus-pertussis and polio 
vaccinations is probably associated with attendance for 
later measles immunisation. Therefore, any separare 
impact of these vaccines has to be examined at ages 
before measles immunisation. The only published 
study of this effect was a case-control study from 
Benin.I6 Relevant data, however, were available from 
both Senegal and Guinea-Bissau. 
We examined the impact of diphtheria-tetanus- 
pertussis and polio vaccines on mortality in children 
between 5 and 10 months of age in Niakhar, SenegaLi 
At 5 months children were called for immunisation and 
some attended and received diphtheria-tetanus- 
pertussis, inactivated polio vaccine, and placebo for 
measles vaccine whereas others did not attend. AI 
10 months of age the children were called again for 
measles immunisation. The estimate of mortality rado 
between 5 and 10 months was adjusted for previous 
immunisations at 3 months of age. 
In Guinea-Bissau we used data from a natimal 
cluster sample of 1 O O00 women of fertile age and their 
prospectively registered pregnancies (authors' unpub- 
lished data). Women of fertile age and their children 
were visited about every six months. In the presen: 
analysis we included only children whose immunisa- 
tion card was seen and children who were assumed KI 
be unvaccinated because they had no card. Children 
aged 2-3 months when first seen should have bem 
immunised with diphtheria-tetanus-pertussis and oral 
polio vaccines and within six months of follow up 
they would not have received measles vaccinc. Some 
children may have received other diphtheria-tctanus- 
pertussis and oral polio vaccines during follow up, bur 
it was not possible to get full immunisation information 
for children who had died, moved, or were absent ar 
the re-examination. To examine whether any vaccine ir 
a marker for better survival we compared mortality of 
children aged 2-3 months during six months of follow 
up -accordmgtuttreiri"unisation-status whcn fim 
seen. 
DEFINITIONS A N D  STATISTICAL METHODS 
We have emphasised the crude estimates of mor- 
tality differences based on deaths by person years at 
TAELE -Studies of measles vaccine 
counay Year Type ofstudy Sample size Measles surveillance* Death ascertainment 
~ - 
Confounder control 
Zaire’t ’ . i974-7 
Guinea-Bissau I‘ 1981-2 
Guinea-BinauIIq 1980 
Guinea-Bissau III‘§ 1984-6 
Guinea-Bissau Wo 1984-7 














Different areas, case-control 
2160 Personyearsatrisk 
211 Children 
,432 Children ‘ 
177 Children 
722 Children 




Three monthly survey 








536 Deaths, 1072 controls Thrice weekly 
Three monthly survey 
Six monthly survey 
Three monthly survey 
Three monthly survey 
Three monthly survey 
Yearly 
Weekly 
Six Months later 











Cement walls, literacy, knowledge of oral rehydration 
Sex, family size, education, ownership of land, 
solution, spacing 
religion 
Bangladesh IPyt 1982-5 Different areas 16 270 Children Thrice weekly Thrice weekly I Sex, parity, size ofdwelling, education 
Benin’% 1986-7 Same area, case-control 74 Deaths, 230 controls 18 Months later 18 Months later Socioeconomic status, weight for age, other vaccines 
‘Interval between collection ofinformation on measles disease. Activezcase identified during active phase of disease. 
s o m p a r e d  immunised children in one area with unimmunised children in a different area. 
$Mortality compared for children attending outreach clinic who were vaccinated against measles with children who did not attend because of temporary absence. In year before introduction of 
vaccine mortality was the same in those who did and did not attend clinic. 
$Study represents “natural experiment.” During one year blood samples were collected before and after vaccination. When samples were analysed with delay of two years, it tumed out that during 
short penad of three weeks, children had not semconverted. These children can be considered to have received “placebo.” Mortality is compared for “placebo” recipients and seroconverten in 
same study. Study has been considered to compare w o  different groups rather than immunised and unimmunised within same community. 
l r w o  measles vaccination campaigns were carried out in certain villages in one rural area of Senegal. Immunised children were compared with children from unimmunised villages. Only children 
immunised before 3 years of age have been included in the present analysis to make age range comparable with age of immunisation used in most other studies. 
YAge adjusted information according to vaccination and measles disease status was not included in paper but was provided by authors (RT Chen, personal communication). 
*Study provided estimates for children according to antibody status at time of immunisation and according to seroconversion. In present analysis, we compared all immunised children, irrespective 
of initial antibody titre, with unvaccinated children as this is available information from other studies. Specific penon years at  risk were not reported, but it has been assumed that all survivors were 
followed on average for 30 months and children who died for 6 months. 
HBefore introduction of measles immunisation mortality was similar in two areas being compared. After 1985, when children in control district had also received measles immunisation, mortality 
in two areas was again similar (authors’ unpublished observations). 
#Published paper reports only efficacy by age at vaccination (S  12 months and > 12 months). Combined estimate for all ages is presented here P Velema, personal communication). 
risk available for all the follow up studies, but available Results 
multivariate estimates adjusted for significant back- REDUCTION IN CHILDHOOD MORT- AFTERSTANDARD 
ground factors have also been noted in table II. Vaccine TITRE MEASLES VACCINE 
efficacy against death (VED) was calculated as one Table II shows that in all 10 follow up studies the 
minus the mortality rate ratio between immunised and impact on mortality after standard measles immunisa- 
unimmunised children. We tested the homogeneity of tion was large, showing reductions in the range of 
the estimates of vaccine efficacy against death-that is, 30-86%. The two case-control studies suggested 
the hypothesis of no interaction between study and the similar reductions in mortality. Crude and adjusted 
size of the vaccine effect.!’ The Mantel-Haenszel estimates were virtually identical. All follow up studies 
estimator was used to combine.results íì-om different showed large reductions, but the estimates of vaccine 
subgroups. efficacy again2t death were heterogeneous (test for 
Death from acute measles is usually defined as any homogeneity, x2=26*3; df=9; P=0.002; figure), 
death within one months or six weekP of a measles The follow up studies were of two kinds. The first 
rash. In the present analyses we used the definition kind compared attenders and non-attenders within the 
used by the study in question. Mortality after measles same community; vaccine efficacy against death was in 
was considered as any death after the acute phase the rangepf 38-86%. ’In studies comparing immunised 
of measles, irrespective of whether it could be and un$pmunised children from different communities 
directly linked to measles disease. The possible impact . estimates, of vacc%e efficacy against death were less 
of immunisation beyond the prevention of measles heterbgeneous, showing estimates in the range of 
disease was assessed by comparing the mortality of 30-67%. Other forms of heterogeneity, however, may 
immunised, uninfected children and unimmunised, have been more important for the variation in estimates 
uninfected children. This was possible in four studies in table II. The impact tended to be greatest in the 
‘(Guinea-Bissau III and IV, Senegal II and Burundi) by studies when children were immunised earlyS and 
censoring follow up atthe time of measles disease, thus which had a shoq.follow up. For example, in seven 
excluding both death after acute measles and deaths . ’studies from Zaire, Guinea-Bissau (I-IV), and Senegal 
after measles. , (I-II) with further data available vaccine efficacy , 
l .  
, TABLE n-MortaIig (deatWperson years at rirk) and vaccine &cay against death of standard titre measks vaccine 
Vaccine efficacy (%) 
Age at Median Mortality (95% confidence intend) 
Measles deaths among 
I Country (months) (months) Unvaccinated Vaccinated Crude Adpsted* unvaccinated children 
vacmation , followup , 
482 
Follow up studies 
Immunised and unimmunised from same commumty 
Guinea-Bissau I 6-36 13 5175.3 
Guinea-Bissau II ” 6-35 12 10/70.5 ’ 
Guinea-Bissau QI 9-23 19 3U367.5 
Senegal II 9-18 23 8611610.5 
Haiti ~ 6-13 30 70/2500.0 
Immunised and unimmunised children from different communitiedgmups 
Zaire 7-9 24 66/1811.2 
Senegal I 6-35 32 11OU6699 
Bangladesh II 9-60 22 339/14940 
Bangladesh I 9-60 536 deaths 
Benin 9-23 74deaths 
‘ Burundi 9-23 15 5111083.4 












38 (-95 to SO) 
86 (64 to 95) 
64 (37 to 79) 
40 (19 to 55) 
75 (55 to 86) 
86 (55 to 96) 
53 (-9 to 80) 
44 (33 to 53) 
67 (3 to 89) 
30 (6 to 48) 
36 (21 to48) 








66 (32 to 83) 
90 (59 to 98) 
83 (35 to 95) 
46 (35 to 95) NA 
29% (U7) 
14% (155/1104) 
36 (20 to 50) 4% (211536)t * 9% (7n4)t 
*Adjusted for significant background factors for mortality (see table 1). 
tIn case-control studies proportion of deaths due to measles is related to total group of deaths and not to group of un immunid  children. 
$Estimates were said to be the same in multivariate analysis. 
NA=not available. 
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Measles vaccine &cacy against 
death in I O studies from 
denelo$ing countries. Solid 
squares repesent vaccine e $ c q  
against dearh (one minus the rate 
mhb of mortah&) in iddual 
studies andlines denote 95% 
conjiaence intervals. Size of 
squares is proportMnal w 
reciprocal variance of estimate, 
amount of "information" 
conhihted w thatstuay, also 
giuen by appmximate weights in 
percentage of total amount of 
infanation in all lostudies. 
: study. . 
Guinea-Bissau I f  
Guinea-Bissau I I  
Guinea-Bissau IV 






Bangladesh I I  
I 
Approximate weight (%) 
I 
- 2  - 5 
& 17 






-25 O 2s 50 75 I O0 
Vaccine efficacy against death (x) 
against death was higher, being in the range of 
44-1000/, when the analysis was limited to one year of 
follow up for children immunised in infancy than in the 
residual part of these studies (data available on request). 
In the Bangladesh II study, in which the mortality data 
were presented in three monthly intervals,15 vaccine 
efficacy against death was significantly greater in 
the first 24 months after immunisation (48%; 95% 
confidence interval 37% to 57%) than in the last 
21 months of the study (6%; -46% to 40%) (x2=5.75; 
df=l; P=0.016). There were similar tendencies in the 
studies from Zaire, Senegal II, and Guinea-Bissau IV 
(data available on request). 
STANDARD TITRE MEASLES VACCINE: PREVENTION OF 
ACUTE AND LONGTERM CONSEQUENCES OFMEASLES 
As indicated in table II all studies found the 
reduction in mortality after measles immunisation 
to be much larger than the proportion of deaths 
attributed to acute measles disease. It has therefore 
been speculated that the prevention of delayed deaths 
from measles could explain the reduction? This could 
be tested by comparing mortality of unimmunised and 
immunised children after the exclusion of all cases of 
measles. If the impact of vaccine was related only to 
the specific prevention of the acute and long term 
consequences of measles disease there should be no 
difference in mortality according to immunisation 
status among uninfected children. This, however, was 
not the case in any of the studies (table m). In the three 
larger studieduinea-Bissau IV, Senegal II, and 
Burundi-there was no change in vaccine efficacy 
against death after exclusion of all cases of measles. 
Hence, in these studies the prevention of measles con- 
tributed little to the reduction in mortality associated 
with immunisation. 
DIPHTHElUA-TETANUS-PERTUSSIS AND POLIO 
IMMUNISATIONS: NO ASSOCIATION WITH REDUCED 
CHILDHOOD MORTALITY 
We also examined the impact of diphtheria-tetanus- 
pertussis and polio vaccines in areas where measles 
immunisation had been studied. In the case-control 
study from Benin recipients of one dose of diphtheria- 
tetanus-pertussis and oral polio tended to have higher 
mortality than unimmunised children (relative 
risk=2-20; 95% confidence interval 0.93 to 5.22).16 
In the vaccine trial from Senegal II (table IV) the 
638 children attending at 5 months and receiving 
diphtheria-tetanus-pertussis - and inactivated polio 
vaccine (and placebo for measles vaccine) had slightly 
but not significantly higher mortality between 5 and 10 
months of age than the 607 children not attending 
immunisation at 5 months (Mantel-Haenszel, mor- 
tality ratio= 1.60; 0.76 to 3.37). In the cluster cohort 
study of 10 O00 women of fertile age and their children 
in Guinea-Bissau 488 children were 2-3 months old 
when first.seen..During six months of follow up 
mortality was 4% (9/245) for children who had already 
received diphtheria-tetanus-pertussis and oral polio 
vaccines at least once and 3% (8/243) for children who 
had not received these vaccines. 
Discussion 
In our analysis of studies on the protective efficacy 
against death of standard measles immunisation we 
found a reduction in mortality in the range of 30-86% 
A major reduction in mortality after measles immuni- 
sation is also supported by a few studies comparing 
mortality rates before and after the introduction 
of measles va~cination.'~ 2o Though estimates were 
heterogeneous the reduction in mortality was consider- 
ably larger in all studies than the share of deaths 
attributed to acute measles disease in the same areas 
(table II). Surprisingly, the protective efficacy of 
measles vaccine was virtually unchanged when follow 
up was discontinued at the date of measles disease, 
suggesting that the reduction in mortality after measles 
immunisation may have liple to do with the specific 
prevention of measles. Subclinical measles infection is 
rare after the age of measles immunisation,'' and ir 
seems therefore unlikely that undetected measles 
infection is a major cause of higher mortality in 
the unimmunised group, particularly because clinical 
measles explained little of the difference in mortality. 
Several other observations also support the possibility 
that measles vaccine has non-specific effects. Contrary 
to expectations, several studies indicated that measles 
immunisation is particularly effective when given early 
in life."57916 Furthermore, the reduction in mortality 
may be the greatest during the first year after immuni- 
sation as a higher vaccine efficacy was observed when 
the follow up period was limited to one year.71orr14 
Though few studies have reported data by sex it seems 
that standard vaccine may be more beneficial for girls 
than for boys.'* l9 22 
Double blind placebo trials of standard titre measles 
vaccine on mortality in developing countries have not 
been performed, and as differences in mortality were 
not explained by prevention of measles the difference 
between immunised and unimmunised children could 
reflect an association between measles immunisation 
and access to other health interventions or a selection 
bias. Most studies (Bangladesh I and II, Guinea-Bissau 
I, II, and III, Senegal I, Zaire) excluded an association 
with other health interventions because measles 
TABLE m-Measles vaccine e$cacy against death, including and 





Study measles cases) measles 
Guinea-Bissau III 67 (3 to 89) 4 
Guinea-Bissau IV 64 (37 to 79) 13 
4 0 ( 1 9 t o 5 5 )  8 Senegal II 





cases meanlei cam) 
20 35(-1621084) 
125 65(35to81) 
9 2  40(IRIo%) 
357 74  (4R 10 87) 
TABLE W-Moitahy between 5 and I O  months of age accmdíng 10 
status for diphtheria-tetanus-pertussis and inactivated polio v& 
(DTF-IPI?l vaccination, Niakhar, Senegal, 1987-9 
Deaths/population (%) for DTP-1f.V 
vaccinear5 months 
Previous DTP-IPV 
immunisation at 3 months Immunised Unimmunitcd 
Yes 6/113 (5%) 10/31R (3%) 
No 111525 (2%) 41269 (1%) 
Total 17/638 (3%) 14/607 (2%) 
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t. I Key messages 
~ _ _ _ _ _  _____ ~ ~~ 
Studies from developing countries have reported reductions in child- 
hood mortality after the introduction of standard titre immunisation for 
measles 
In 10 cohort studies measles efficacy against death was in the range 
0 The specific prevention of the acute and long term consequences of 
measles disease does not explain the reduction in mortality among immunised 
children 
In three studies diphtheria-tetanus-pertussis and polio vaccines were 
not associated with similar reductions in mortality, making it unlikely that 
selection bias can explain the impact of measles immunisation 
Standard titre measles vaccine seems to be associated with a non-specific, 
beneficial effect which may have important implications for the planning of 
immunisation programmes 
of 30-86% 
immunisation was the only intervention available or 
the only intervention which differed between the areas. 
Most studies (Bangladesh I and II, Guinea-Bissau II, 
III, and IV, Haiti, Zaire) tried to exclude the possi- 
bility that selection bias was the major cause of 
differences in mortality by using multivariate analysis 
to adjust for important determinants of mortality (table 
II), by showing no difference between the groups 
before the introduction of measles vaccine, or by 
comparing those who did not seroconvert because they 
had received a placebo and children who had received 
an effective vaccine. 
A bias due to publication of only those studies with 
significant results seems unlikely as a strong effect of 
measles immunisation has been reported from almost 
all the longitudinal research on measles or measles 
immunisation.‘6-12 I‘ Is ’* l9 23 Though the estimate for 
vaccine efficacy against death was slightly lower 
(30-67%) for the more satisfactory studies comparing 
immunised and unimmunised areas than for the 
other studies (3846%) comparing immunised and 
unimmunised children from the same area, all studies 
documented the same unexplained reduction in 
mortality. 
If a systematic selection bias between attenders and 
non-attenders was the main cause of the clear impact of 
measles immunisation a similar difference in mortality 
could be expected between recipients and non- 
recipients of diphtheria-tetanus-pertussis and polio 
vaccines, particularly as these vaccines are given early 
in life when mortality is high. In the three areas with 
relevant data, there was no indication that immunisa- 
tion with these vaccines were also associated with 
reduced mortality. 
The observation that exclusion of cases of measles 
had little effect on the vaccine efficacy against death 
contradicts previous studies that suggest that measles 
is associated with a significant long term excess 
mortality.‘ 24 Previous studies compared mortality after 
measles with mortality in immunised controls, how- 
ever, rather than with unimmunised children who are 
the appropriate controls if measles immunisation has 
non-specific effects. For example, children who had 
survived the acute phase of measles in Guinea-Bissau 
were found to have significantly higher mortality than 
community controls who had received measles vaccine 
(mortality ratio 4.18; 1.13 to 15.43).‘ Compared 
with unimmunised controls, however, children who 
survived the acute phase did have slightly lower 
mortality (0-45; 0.14 to 1.43). More recent analyses of 
the long term effect of measles disease in Guinea- 
Bissau, Senegal, Bangladesh (authors’ unpublished 
observation), and Burundi” indicate that children who 
survive acute measles have the same or significantly 
lower mortality than non-infected unimmunised 
children. Hence, acute mortality may partly be 
compensated by lower subsequent mortality, and the 
total mortality impact of measles in the unimmunised 
group may be limited. 
If protection against measles disease does not explain 
the impact of measles immunisation on child survival 
the simplest explanation would seem to be that measles 
vaccine activates the immune system in a non-specific 
way providing protection against other infections. 
Studies of immune responses to measles infection 
have mainly focused on immunological abnormalities 
possibly explaining the expected immunosuppression 
and increased susceptibility to other infections leading 
to complications and death.?l Immunological stimula- 
tion by measles disease and immunisation, however, 
may also protect against other infe~tions.~~” For 
example, measles immunisation reduces the incidence 
of diarrhoea (authors’ unpublished observation) and 
may prevent subsequent immunisation with vaccinia.26 
The hypothesis of a non-specific beneficial effect of 
measles vaccine has important practical and theoretical 
implications. If new vaccines do not provide similar 
non-specific effects, new measles vaccines capable of 
immunising in the presence of maternal antibodieszs 
may end up being associated with lower survival than 
standard titre measles vaccine. The available data 
indicate that child survival might benefit from stan- 
dard titre measles immunisation before 9 months of age 
and possibly also from repeated doses of the vaccine.j 
Further studies are obviously needed to explain the 
biological basis and to determine the magnitude of the 
non-specific effects. Such studies may be conducted 
within two dose trials or studies of the impact of 
reimmunisations. Should the hypothesis be correct 
measles immunisation may have to be continued even 
when measles infection has been eradicared. 
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